Trial Profile
A Phase I Safety Study of CRB-4001 for the Treatment of Nonalcoholic Steatohepatitis (NASH)
Planning
Phase of Trial:
Phase I
Latest Information Update: 27 Sep 2018
At a glance
- Drugs CRB-4001 (Primary)
- Indications Fibrosis; Idiopathic pulmonary fibrosis; Interstitial nephritis; Non-alcoholic steatohepatitis; Primary biliary cirrhosis; Pulmonary fibrosis
- Focus Adverse reactions
- Sponsors Corbus Pharmaceuticals
- 27 Sep 2018 New trial record
- 20 Sep 2018 According to a Corbus Therapeutics media release, this trial is expected to begin in 2019.